EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review

Utku Akgör, Bilal Esat Temiz, Hasan Volkan Ege, Laura Burney Ellis, Sarah Bowden, Maria Kyrgiou, Marc Arbyn iD, Mario Preti iD, Kimon Chatzistamatiou iD, Zoia Razumova iD, Vesna Kesic iD, Nicolò Bizzarri iD und 8 weitere

Cancers · 23.07.2026 · 18 (15) · 2374

DOI: 10.3390/cancers18152374 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.07.2026. Verfasst von Utku Akgör und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The levonorgestrel-releasing intrauterine device (LNG-IUD) is widely used as a long-acting reversible contraceptive and as a therapeutic option for heavy menstrual bleeding, endometriosis, adenomyosis, and endometrial hyperplasia. Although its predominant effect is local, systemic levonorgestrel exposure has raised questions regarding its potential influence on cancer risk. This review aims to summarise and critically appraise the available evidence on the association between LNG-IUD use and gynaecologic, breast, and selected non-gynaecologic malignancies (including colorectal, lung, pancreatic, gastric, thyroid, skin [melanoma], and haematological cancers).

Methods

A structured narrative review was developed by a multidisciplinary expert group affiliated with the European Society of Gynaecological Oncology (ESGO) and the European Society for Gynaecological Endoscopy (ESGE). PubMed/MEDLINE, Embase, and Scopus were searched in December 2024 without publication-date restrictions. We critically appraised epidemiological and clinical evidence on LNG-IUD use and breast, endometrial, ovarian, cervical, and selected non-gynaecologic cancer risks, prioritising population-based cohorts, registry-based studies, case–control studies, systematic reviews, and meta-analyses.

Results

The strongest and most consistent evidence supports a substantial reduction in endometrial cancer risk among LNG-IUD users, with a possible protective association also suggested for ovarian cancer. Available data do not indicate a clear increase in cervical cancer, CIN3+, or invasive cervical disease. In contrast, evidence for breast cancer remains heterogeneous, with some registry-based studies suggesting a modest relative increase and other cohort or case–control studies showing no significant association. Evidence regarding non-gynaecologic cancers remains limited and inconclusive.

Conclusions

Overall, current evidence suggests that the LNG-IUD has a favourable oncological safety profile, with the strongest evidence supporting a significant reduction in endometrial cancer risk and a potential protective effect against ovarian cancer. There is no evidence pointing to increased risk of cervical cancer. However, results related to breast cancer are mixed, and a slight risk increase cannot be ruled out; thus, counselling should be personalised based on the indication, menopausal status, duration of use, and individual breast cancer risk.

Schlagwörter

Stichwörter der Autor:innen

breast cancercancer riskendometrial cancerhormonal intrauterine systemlevonorgestrel-releasing intrauterine deviceovarian cancer

Autor:innen und Institutionen

  • Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.
  • Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
  • Belgian Cancer Centre, Sciensano, 1050 Brussels, Belgium.
  • Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
  • 1st Department of Obstetrics and Gynaecology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Karolinska Institute, 171 77 Stockholm, Sweden.

ORCID-Profile: Marc Arbyn, Mario Preti, Kimon Chatzistamatiou, Zoia Razumova, Vesna Kesic, Nicolò Bizzarri, Houssein El Hajj, Bernhard Krämer

Zitieren

APA

Akgör, U., Temiz, B. E., Ege, H. V., Ellis, L. B., Bowden, S., Kyrgiou, M., Arbyn, M., Preti, M., Chatzistamatiou, K., Razumova, Z., Kesic, V., Bizzarri, N., Gassama, O., Hemida, R., Ibraheem, N., El Hajj, H., Raina, D., Collinet, P., Krämer, B., & Gultekin, M. (2026). Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review. Cancers, 18(15), 2374. https://doi.org/10.3390/cancers18152374

Vancouver

Akgör U, Temiz BE, Ege HV, Ellis LB, Bowden S, Kyrgiou M, et al. Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review. Cancers. 2026;18(15):2374. doi:10.3390/cancers18152374

BibTeX
@article{Akgr2026,
  author = {Akgör, Utku and Temiz, Bilal Esat and Ege, Hasan Volkan and Ellis, Laura Burney and Bowden, Sarah and Kyrgiou, Maria and Arbyn, Marc and Preti, Mario and Chatzistamatiou, Kimon and Razumova, Zoia and Kesic, Vesna and Bizzarri, Nicolò and Gassama, Omar and Hemida, Reda and Ibraheem, Nagham and El Hajj, Houssein and Raina, Deepali and Collinet, Pierre and Krämer, Bernhard and Gultekin, Murat},
  title = {Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2374},
  doi = {10.3390/cancers18152374}
}
Kostenlos starten →